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Abstract
In March 2013, an inﬂuenza outbreak caused by the novel avian-origin H7N9 inﬂuenza A virus emerged in eastern China and had caused 43
fatalities by 31 July 2013, although the basis for disease pathogenesis still remains unclear. To assess the immunological and viral factors
associated with disease severity, viral RNA and inﬂammatory cytokines were quantiﬁed for 18 H7N9 patients in Shanghai, China. Detailed
clinical information was collected and clinical laboratory investigations were performed for all patients. H7N9 infection is characterized by
high pharyngeal virus load and frequent detection of viral RNA in blood. High pharyngeal virus load persisted through the ﬁrst 10 days of
antiviral therapy in fatal cases. Genetic characterization of the H7N9 virus revealed an Arg292Lys mutation in the neuraminidase gene
associated with oseltamivir-resistance. Pronounced lymphopenia and high chemokine and cytokine levels were observed in H7N9-infected
patients, particularly in those where disease was fatal. Serum levels of interleukin-6 (IL-6), IL-8 and macrophage inﬂammatory protein-1b in
our subjects also correlated positively with pharyngeal virus load. Lymphocyte counts <0.5 9 109 cells/L, and serum IL-6 >97 pg/mL, IL-8
>40 pg/mL and C-reactive protein >90 mg/L were identiﬁed as being connected with adverse clinical outcome through univariate logistic
analysis. Signiﬁcant survival differences were also observed between patients with serum C-reactive protein <90 mg/L or creatinine
<90 lmol/L and those with higher levels. Our data demonstrated that high viral load, and the resulting intense inﬂammatory responses,
played an important role in H7N9 pathogenesis. Though immunomodulatory treatment has potential beneﬁts, the focus of clinical
management should be on preventing the intense cytokine response by early diagnosis and effective antiviral treatment.
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Introduction
In March 2013, an inﬂuenza outbreak caused by a novel
avian-origin H7N9 inﬂuenza A virus emerged in eastern China
[1,2]. This H7N9 virus had not been detected from humans or
animals previously. Genetic analysis revealed that the viral
genome consisted of six internal genes from avian inﬂuenza A
(H9N2) viruses whereas the haemagglutinin and neuraminidase
gene segments derived from viruses from ducks or wild birds.
Patients usually presented with fever and cough, with early
sputum production, and the illness progressed rapidly to
severe pneumonia, moderate-to-severe acute respiratory
distress syndrome (ARDS) and shock [3]. Up to July, this
novel inﬂuenza A virus had caused infection in 134 individuals
in China, leading to 43 deaths (http://www.who.int/csr/don/
2013_07_20/en/index.html) (Date of access: 2013/7/31).
Global attention was soon focused on the situation because
of the increasing numbers of new cases and the high fatality
rate associated with these infections. Recent studies also
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revealed that the epidemic of H7N9 could possibly reappear in
the autumn because of its epidemiological pattern, which is
similar to H5N1 [4]. This potential lull should be an
opportunity for discussion of deﬁnitive preventive public
health measures and optimization of clinical management. To
better understand the H7N9 infections, we describe here the
host immunological response and clinical features of 18
patients with inﬂuenza A/H7N9 infection who have been
admitted to the Shanghai Public Health Clinical Centre
(SPHCC) since April 2013.
Materials and Methods
Patients
Eighteen patients who were diagnosed with inﬂuenza A/H7N9
infection at the Shanghai Municipal Centre for Disease Control
and Prevention, Shanghai, China were included in the present
study. When the infections were conﬁrmed, these patients
were immediately transferred to the SPHCC for further
treatment. The demographic details, co-morbidities, viral
detection, treatment and ﬁnal disposition of these patients
are all outlined in Table 1. Systematic clinical laboratory tests
were performed for each individual throughout hospitalization.
The study protocol was approved by the ethics committee of
the SPHCC.
Quantitative assay of viral RNA
Viral RNA was extracted from 140 lL of the virus transport
medium in throat swab vials and serum using a QIAamp
Viral RNA Mini Kit (Qiagen, Valencia, CA, USA). Quantita-
tive RT-PCR was performed with a one-step ﬂuorescent
quantitative RT-PCR kit (TaKaRa Bio, Dalian, China) as
described previously [5]. Viral RNA concentration was
quantiﬁed by running a real-time PCR in parallel with
standards with a known number of copies of the haemag-
glutinin gene cloned in the plasmid pMD 18-T vector. The
detection limit of the assay was one hundred copies of
cDNA per millilitre.
Serum cytokine and chemokine measurement
Serum cytokines (interleukin-6 (IL-6), IL-8, IL-10, interferon-c
and tumour necrosis factor-a) of the 18 H7N9 patients were
determined using a human inﬂammatory cytokine kit (BD
Biosciences, San Jose, CA, USA) according to the manufac-
turer’s instructions. Data acquisition was performed on BD
FACSAria II (BD Biosciences). Data were analysed on CBA
analysis software. Serum macrophage inﬂammatory protein-1b
(MIP-1b) was measured by ELISA (BioLegend, San Diego, CA,
USA) according to the manufacturer’s protocols.
Statistical analysis
The quantitative variables in asymmetric distributions were
expressed as median (interquartile range, IQR), whereas the
measurement data in symmetric distributions were presented
as means  standard deviation (SD). Comparisons between
groups were performed through the Kruskal–Wallis rank sum
test and Student’s t test for quantitative variables in asymmet-
ric or symmetric distributions, respectively. Categorical vari-
ables were summarized as numbers (percentages). Pearson’s
two-sided chi-square test or, if the expected count in any cell
was less than ﬁve, Fisher’s exact test was used to compare
binary data. Correlations between viral load and immunolog-
ical parameters in specimens obtained on the same day were
TABLE 1. Clinical features and virus detection in 18 H7N9
infected patients
Total
(n = 18)
Group A
(n = 12)
Group B
(n = 6)
Age, median years (IQR) 71 (62–78) 67.5 (63.5–74.5) 76.5 (58–87)
Male sex 14/18 9/12 5/6
Direct contact with live poultry
in previous 7 days
3 (16.7) 1 (8.3) 2 (33.3)
Time from illness
onset to antiviral
therapy, median days (IQR)
6.5 (5–8) 7 (5–8.5) 6.5 (6–7)
Time from illness onset
to hospitalization,
median days (IQR)
7 (6–9) 7 (5.5–8.5) 8 (6–11)
Underlying medical disorders
Hypertension 7 (38.9) 5 (41.7) 2 (33.3)
Diabetes 4 (22.2) 3 (25) 1 (16.7)
Coronary heart disease 5 (27.8) 3 (25) 2 (33.3)
COPD 2 (11.1) 1 (8.3) 1 (16.7)
Detection of H7N9 virus
Detectable RNA in throat
swabs (positive/tested; %)
15/17 (88.2) 11/12 (91.7) 4/5 (80)
Viraemia (positive/tested; %) 6/14 (42.9) 4/10 (40) 2/4 (50)
Symptoms
Fever 18 (100) 12 (100) 6 (100)
Fatigue 16 (88.9) 11 (91.7) 5 (83.3)
Cough 16 (88.9) 11 (91.7) 5 (83.3)
Sputum production 11 (61.1) 8 (66.7) 3 (50)
Shortness of breath 9 (50) 4 (33.3) 5 (83.3)
Myalgia 3 (16.7) 3 (25) 0
Diarrhoea 2 (11.1) 2 (16.7) 0
Chest pain 1 (5.6) 1 (8.3) 0
Complications
ARDS 5 (27.8) 1 (8.3) 4 (66.7)*
Heart failure 7 (38.9) 2 (16.7) 5 (83.3)*
Acute kidney injury 4 (22.2) 1 (8.3) 3 (50)
Septic shock 3 (16.7) 0 3 (50)*
Treatment
Antiviral therapy
(oseltamivir)
18 (100) 12 (100) 6 (100)
Oxygen therapy 18 (100) 12 (100) 6 (100)
Non-invasive mechanical
ventilation
8 (44.4) 2 (16.7) 6 (100)*
Extracorporeal membrane
oxygenation
3 (16.7) 0 3 (50)*
Antibiotics 18 (100) 12 (100) 6 (100)
Glucocorticoids 14 (77.8) 9 (75) 5 (83.3)
Intravenous immunoglobulin 9 (50) 6 (50) 3 (50)
Clinical outcome
Discharged 12 (66.7) 12 (100) 0*
Death 5 (27.8) 0 5 (83.3)*
ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmo-
nary disease; IQR, interquartile range.
Data are given as numbers (percentages) except where otherwise indicated.
Group A, non-fatal cases group, all patients recovered within 40 days after the
onset of illness; group B, fatal and serious cases group, patients experienced either
death or prolonged hospitalization. One patient in group B was still hospitalized at
the time of the study.
*p <0.05 when compared with group A, chi-square test.
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calculated using Spearman’s rank correlation test. Considering
the limited number of cases, univariate logistic regression
models, instead of multivariate analysis, were employed to
identify the risk factors associated with adverse clinical
outcome. The Kaplan–Meier product-limit method was used
to analyse patient survival. Patients who were discharged from
the hospital were proved to survive till the conduction of the
present study. The log-rank test was used to compare survival
distributions. Data analysis was carried out with INTERCOOLED
STATA v.7 FOR WINDOWS; p <0.05 was considered to be
statistically signiﬁcant.
Results
Demographic and epidemiological ﬁndings
This study described 18 patients with conﬁrmed inﬂuenza A/
H7N9 infection admitted to SPHCC since April 2013. Demo-
graphic, epidemiological and clinical characteristics of the
patients at admission are shown in Table 1. The 18 patients
had a median age of 71 years (IQR 62–78), and 14 (77.78%) of
them were male. A total of 14 (77.78%) patients had one or
more coexisting medical conditions. Hypertension, coronary
heart disease, diabetes and chronic obstructive pulmonary
disease were the most common underlying medical disorders.
According to the clinical notes, only three patients had direct
contact with live poultry in the 7 days before illness onset.
Patients presented to the hospital after a median duration of
illness of 7 days (IQR 6–9). The 18 H7N9 patients were
divided into two groups: patients discharged within 40 days
after illness onset (group A, 12 cases) and patients who either
passed away or remained hospitalized in a severe condition
(group B, six cases). The two groups did not differ signiﬁcantly
in age, sex ratio, days from illness onset to hospital admission
and days from illness onset to commencement of oseltamivir
therapy (Table 1).
Clinical features
As shown in Table 1, fever, fatigue and cough were the most
common ﬁndings at initial assessment, and sputum production
and shortness of breath were also observed in more than half
of the patients. Four patients in group B and one patient in
group A developed moderate-to-severe ARDS. Heart failure,
acute kidney injury and septic shock were also common
complications. For the incidence of ARDS, heart failure and
septic shock, statistically signiﬁcant differences were spotted
between the two patient groups. Of the ﬁve patients with
ARDS, all received non-invasive mechanical ventilation and
three individuals in group B became extracorporeal membrane
oxygenation-dependent. ARDS also proved to be correlated
with adverse clinical outcome through univariate logistic
analysis (Table 4) and statistically signiﬁcant survival difference
was also observed between patients who developed ARDS and
those who did not (Fig. 3a). Besides, all patients received
oseltamivir as antiviral treatment, and the median time from
the illness onset to the initiation of antiviral therapy was
6.5 days (IQR 5–8). Antibiotics and oxygen therapy were also
given to all patients.
The viral dynamics of H7N9 patients
The viral loads in patients’ throat and serum were determined
immediately when admitted. Patients received neuraminidase
inhibitor treatment on diagnosis, so it became impossible for
us to determine the natural viral dynamics. However, viral load
in throat swabs collected from patients on admission taken as
a whole may provide an insight into the viral dynamics over the
course of the illness before prolonged therapeutic interven-
tions. The median of viral loads in throat swabs taken just after
admission in the two groups were as follows: 2.94 (IQR 2.26–
3.37) in group A and 4.19 (IQR 3.10–4.68) in group B. Though
the overall viral load in group B was higher than that in group
A, no statistically signiﬁcant relationship was observed
(p 0.0720). Besides, viral load in the throats of group A
patients decreased rapidly, and only two individuals in this
group were still positive for H7N9 virus after 10 days of
antiviral therapy, whereas high viral load persisted in group B
patients through the same period (Fig. 1a). Three patients in
group B with persistently high viral loads in their throats in
spite of antiviral therapy became extracorporeal membrane
oxygenation-dependent. This high viral load had been proved
to be partially induced by the emergence of an oseltami-
vir-resistance-associated Arg292Lys mutation (position 292
with N2 numbering; position 294 with N9 numbering) in
neuraminidase protein through high-throughput and Sanger
sequencing, which also led to treatment failure and adverse
clinical outcome [5]. However, it is also important to note that
neither duration of illness before being admitted nor the viral
load in patients’ throats correlated with the clinical outcome
(Table 4). Viral RNA could also be detected in blood
specimens from 6 of 14 H7N9-infected individuals (Table 1).
For the incidence of viraemia, no statistically signiﬁcant
difference was spotted between group A and group B.
Cytokine proﬁles
To determine the role for innate immunity in H7N9 infection,
serum inﬂammatory cytokines were quantiﬁed upon patient
admission. As shown in Table 2, IL-6 and IL-8 were the most
elevated among different cytokines, while MIP-1b increased at
intermediate levels. Interleukin-6, IL-8 and MIP-1b were
signiﬁcantly higher in group B than those in group A
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(p <0.01). Serum IL-6 >97 pg/mL and IL-8 >40 pg/mL were
also proved to be correlated with adverse clinical outcome
through univariate logistic analysis (Table 4). Moreover, serum
levels of IL-6, IL-8 and MIP-1b in our subjects correlated
positively with H7N9 viral load in throat swabs (Fig. 2).
Clinical laboratory characteristics
Table 3 lists the clinical laboratory investigations of the 18
H7N9 patients. The abnormality of laboratory indicators was
deﬁned as previously described [6]. All patients had pro-
nounced lymphopenia (<1.5 9 109 lymphocytes/L) at presen-
tation, which was recognized as the most common
haematological abnormality, and lymphocyte counts in group
B were signiﬁcantly lower than in group A (p <0.05). The
dramatic reduction of T-lymphocyte subsets (CD3, CD4 and
CD8) was also present in all patients. The lymphocyte counts
in group A rebounded rapidly after admission; in group B,
however, this indicator remained at low levels after 10 days of
antiviral therapy (Fig. 1b). Lymphocyte counts <0.5 9 109
cells/L were found to be correlated with adverse clinical
outcome through univariate logistic analysis (Table 4).
Thrombocytopenia (<1.5 9 109 platelets/L) was also a
common ﬁnding, and was noted for 13 (72.2%) patients. The
coagulation proﬁles of all patients were impaired and the levels
of ﬁbrin degradation product and D-dimer substantially
increased. Similarly, signiﬁcant higher levels of C-reactive
protein (CRP) were also present in all patients and serum CRP
was higher in group B (p <0.05) (Table 3). Moreover, elevated
aspartate aminotransferase was present in all patients, while an
increase of serum creatinine and urea was observed in group
B, indicating the occurrence of acute kidney injury in early
H7N9 infection. Serum creatinine >90 lmol/L and CRP
>90 mg/L were identiﬁed as risk factors for poor prognosis
through univariate logistic analysis (Table 4) and statistically
signiﬁcant survival differences were also observed between
patients with serum creatinine <90 lmol/L, CRP <90 mg/L and
those with higher levels (Fig. 3). A slight decrease of PO2 in
arterial blood was also spotted in all patients, which is the only
laboratory abnormality in arterial blood gas tests.
Discussion
Host innate immune responses and systematic clinical features
were described for the 18 H7N9 patients who had been
admitted to the SPHCC since April 2013. The demographics of
these 18 patients were broadly similar to those of the ﬁrst 82
patients reported by Li et al. [7]. The clinical features of
hospitalized H7N9 patients were generally similar to individ-
uals with severe pandemic H1N1 or H5N1 infection. Patients
usually presented with fever, cough and early sputum produc-
tion, and the illness progressed rapidly to severe pneumonia,
moderate to severe ARDS, and shock [3]. Interestingly,
patients who were hospitalized with H7N9 infection had an
uneven age distribution, with 42.3% being 65 years or older
[3]. This was similar to that for seasonal inﬂuenza, but differed
greatly from the age distribution of patients who were
(a) (b)
FIG. 1. Thedynamics of viral load in throat (a) and lymphocyte counts (b) in patients infectedwithH7N9.GroupA (12 cases) is thenon-fatal cases group,
comprising all patientswhorecoveredwithin 40 days after theonsetof illness; groupB (six cases) is the group comprising patientswhoexperiencedeither
death or prolonged hospitalization. Variableswere presented asmedians, and viral load under the detection limitwas deﬁned as 0. A total of three patients
died in group B up to the 12th day of antiviral therapy, so variables obtained in the following period were not presented for this group.
TABLE 2. Levels of cytokines and chemokine in serum of
patients with H7N9 infection
Total
(n = 18)
Group A
(n = 12)
Group B
(n = 6) p
IL-6 64.15 (21.9–126.5) 31.6 (17.5–64.15) 181.8 (114.8–215.9) 0.0020
IL-8 31.6 (17.8–46.2) 22.4 (12.95–31.6) 57.45 (43.5–76.5) 0.0015
IL-10 8.55 (6.8–13.4) 7.9 (4.85–11.2) 12.7 (8.2–27.4) 0.1113
TNF-a 6.7 (3.6–8.4) 6.7 (4.2–8.45) 6.3 (3.6–7.4) 0.7075
IFN-c 6.45 (4.6–11.2) 5.55 (4.45–9.7) 9.35 (4.6–11.8) 0.5121
MIP-1b 20.8 (7.7–27.1) 10.65 (7.2–25.15) 28.45 (25.4–32.5) 0.0168
IFN-c, interferon-c; IL-6, interleukin-6; MIP-1b, macrophage inﬂammatory pro-
tein-1b; TNF-a, tumour necrosis factor-a.
Data were given as median pg/mL (interquartile range).
The p-value reﬂected group A versus group B through Kruskal–Wallis rank sum
test.
Group A, non-fatal cases group, all patients recovered within 40 days after the
onset of illness; group B, fatal and serious cases group, patients experienced either
death or prolonged hospitalization.
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hospitalized with H1N1 or H5N1 infection, the latter being
predominantly younger individuals [8,9]. The fatality risk of
H7N9 infection for all ages was estimated to be 36% (95% CI
26–45) on admission, which is not as severe as inﬂuenza A
H5N1, but is more severe than inﬂuenza A H1N1 [10].
Fortunately, limited or sustainable human-to-human transmis-
sion was still not noted on observation of a large number of
individuals in close contact with patients.
We noted that oseltamivir treatment was associated with
falling viral load in the respiratory tract in the majority of
patients, whereas high viral load persisted in group B over the
ﬁrst 10 days of antiviral therapy. This was later conﬁrmed to
be associated with the emergence of an Arg292Lys (R292K)
mutation in the virus neuraminidase gene [5]. Clinically, the
R292K mutation in seasonal H3N2 inﬂuenza virus is known to
confer resistance to oseltamivir [11]. This mutation was also
(a) (b) (c)
FIG. 2. Correlations between pharyngeal virus load and serum cytokines in H7N9 infection. (a) Correlations between pharyngeal viral RNA load
and serum interleukin-6 (IL-6) (Pearson r = 0.5452, p 0.0356). (b) IL-10 (Pearson r = 0.6275, p 0.0123). (c) Macrophage inﬂammatory protein-1b
(MIP-1b) (Pearson r = 0.5870, p 0.0416). No signiﬁcant correlations were observed for lymphocyte counts (r = 0.3295, p 0.2305) and serum
C-reactive protein (r = 0.5090, p 0.0527).
TABLE 3. Clinical laboratory pre-
sentations of patients on admission
with inﬂuenza virus A/H7N9 infec-
tion
Normal range Group A (n = 12) Group B (n = 6) Total (n = 18)
Blood routine tests
White blood cells (9109 cells/L) 4.00–10.00 4.84 (3.37, 7.14) 6.04 (5.41, 7.05) 5.45 (3.76, 7.05)
Haemoglobin (g/L) 113.00–151.00 135.08  13.86 123.33  23.11 131.17  17.71
Platelets (9109 cells/L) 101–320 126.56  56.43 113.67  43.42 122.28  51.52
Neutrophils (9109 cells/L) 2.00–7.00 3.66 (2.60, 6.21) 5.48 (4.89, 6.19) 4.95 (3.07, 6.19)
Lymphocytes (9109 cells/L) 0.80–4.00 0.66  0.20 0.36  0.19* 0.56  0.24
Blood coagulation tests
Fibrin degradation product (mg/L) 0.00–5.00 13.75  5.29 25  8.37* 17.5  9.74
D-dimer (mg/L) 0.00–0.50 1.38  0.83 2.5  0.84* 1.75  0.97
Clinical immunology
Complement 3 (g/L) 0.79–1.52 0.89  0.31 0.64  0.26 0.81  0.31
Complement 4 (g/L) 0.16–0.38 0.24  0.08 0.19  0.06 0.22  0.08
IgA (g/L) 0.82–4.53 1.98 (1.65, 2.21) 2.13 (1.97, 2.40) 2.03 (1.68, 2.21)
IgG (g/L) 7.51–15.60 12.89  4.72 13.32  3.08 13.04  4.15
IgM (g/L) 0.46–3.04 1.08 (0.75, 1.38) 1.20 (0.80, 1.90) 1.09 (0.76, 1.52)
CD3 lymphocytes (cells/lL) 690–2540 460.58  229.13 222.50  115.81* 381.22  226.39
CD4 lymphocytes (cells/lL) 410–1590 307  168.46 166.33  90.23* 260.11  159.42
CD8 lymphocytes (cells/lL) 190–1140 142.75  66.89 55.50  36.45* 113.67  71.26
C-reactive protein (mg/L) <8.00 60.26  36.15 122.93  38.44* 81.15  46.95
Liver function
Alanine aminotransferase (U/L) 5.00–40.00 56.92  28.71 32.67  10.17 48.83  26.50
Aspartate aminotransferase (U/L) 8.00–40.00 75.83  37.57 76.50  67.25 76.06  47.37
Cardiac function
Creatine kinase-MB (U/L) 0.00–24.00 21.75  11.75 29.33  21.59 24.28  15.49
Cardiac troponin T (ng/mL) <0.05 <0.05 <0.05 <0.05
Myoglobin (ng/mL) 7.00–64.00 102.58  49.71 232.20  68.55* 140.71  90.67
Renal function
Creatinine (lmol/L) 45.00–104.00 71.89  14.24 131.92  35.05* 90.7  26.32
Urea (mmol/L) 1.70–8.30 6.61  3.24 10.07  6.37* 7.76  2.64
Arterial blood gases
pH 7.35–7.45 7.44  0.05 7.40  0.07 7.43  0.06
PCO2 (KPa) 4.30–6.00 4.81  1.23 4.70  1.10 4.77  1.16
PO2 (KPa) 10.00–14.00 8.03  1.78 8.60  2.54 8.19  1.97
Bicarbonate (mmol/L) 22.00–29.00 23.89  4.17 21.10  3.39 22.96  4.06
Oxygen saturation (%) 91.90–99.00 91.64  3.91 90.38  5.24 91.22  4.28
Variables in asymmetric distribution were expressed as median (interquartile range), while data in symmetric distribution
were presented as means  standard deviation.
Group A, non-fatal cases group, all patients recovered within 40 days after the onset of illness; group B, fatal and serious
cases group, patients experienced either death or prolonged hospitalization.
Bold indicators revealed that the values in patient groups differ signiﬁcantly from the normal range.
For platelet counts, despite the normal range of 101–320 9 109 cells/L, thrombocytopenia was deﬁned as <1.5 9 109
platelets/L according to ‘Age-appropriate vital signs’ released by the National Institutes of Health Clinical Center [6].
*p < 0.05 when compared with group A, Student’s t test.
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present in an H1N9 virus, conferring resistance to zanamivir
and oseltamivir [12]. According to a neuraminidase inhibition
assay, an R292K substitution reduced the antiviral efﬁcacy of
inhibitors, especially oseltamivir, and decreased viral ﬁtness in
cell culture [13]. The efﬁcacy of neuraminidase inhibitors in
clinical management of H7N9 infection may be compromised
to a certain extent when R292K is present. Animal model
studies are needed to aid in the understanding of the clinical
relevance of R292K.
Viral RNA could also be detected in blood specimens from
6 of 14 H7N9-infected individuals. For H1N1 infection, the
occurrence of viraemia was strongly associated with a severe
clinical presentation and a higher mortality rate [14]. Though a
similar phenomenon was also observed in H5N1 infection,
viral RNA in blood was only present in fatal H5N1 cases and
was associated with higher pharyngeal viral loads, no corre-
lation of viraemia with clinical outcome in H7N9 infection was
determined [15]. Viral RNA might represent non-infectious
virus rather than infectious virus particles, but it is important
to investigate whether H7N9 virus disseminates beyond the
respiratory tract.
Innate immunity, showing as inﬂammatory cytokine
responses, played a pathogenic role in early H7N9 infection
and higher levels of inﬂammatory cytokines were correlated
with adverse clinical outcome. Measurement of serum cyto-
kines revealed elevated levels of IL-6, IL-8 and MIP-1b, and the
coincident rise of CRP indicated that a co-infection with
bacteria may occur and thereby aggravate the severity of
infection. Although levels of cytokines in lung tissue may be
more relevant to pathogenesis than levels in blood, it is likely
that blood cytokine levels reﬂect the pattern of diffusion from
the highly vascular lung. Our data proved that the early
inﬂammatory cytokine responses could be viewed as a window
for monitoring the severity of inﬂammation. In vitro infection of
TABLE 4. Factors associated with adverse outcome analysed
by univariate logistic regression analysis
Risk factor
Odds
ratio 95% CI p value
ARDS cases 22 1.54–134.29 0.023
Viral load in throat >3.75 log10
cDNA copies/mL
12 1.94–53.88 0.056
Serum IL-6 > 97 pg/mL 55 2.83–168.35 0.008
Serum IL-8 > 40 pg/mL 55 2.83–168.35 0.008
Lymphocyte count <0.5 9 109 cells/L 10 1.03–59.50 0.048
C-reactive protein >90 mg/L 25 1.80–146.68 0.016
Creatinine >90 lmol/L 22 1.54–134.29 0.023
Urea >12 mmol/L 11 2.82–47.86 0.070
Time from illness onset to
hospitalization >7 days
1.4 0.20–10.03 0.738
Time from illness onset to initiation
of antiviral therapy >5 days
3.57 0.31–40.75 0.305
ARDS, acute respiratory distress syndrome; IL-6, interleukin-6.
The cut-off values were determined through receiver operating characteristic
curve analysis.
All laboratory indices referred to the values of patients presented on admission.
(a)
(b)
(c)
FIG. 3. Survival plot for patients with H7N9 virus infection divided by
acute respiratory disease syndrome (ARDS) cases, serum C-reactive
protein (CRP) and creatinine. Patients who were discharged from the
hospital because they were cured were found to survive after
discharge. (a) Survival distribution comparison between patients who
developed ARDS and those who did not. ARDS cases versus
non-ARDS cases, p 0.0010, calculated by log-rank test. (b) Survival
curve comparison between patients with serum CRP <90 mg/L and
patients with higher levels. CRP <90 mg/L versus CRP >90 mg/L,
p 0.0078, calculated by log-rank test. (c) Survival distribution compar-
ison between patients with serum creatinine <90 lmol/L and those
with higher levels. Serum creatinine <90 lmol/L versus creatinine
>90 lmol/L, p 0.0022, calculated by log-rank test.
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bronchial epithelial cells and macrophages with H5N1 viruses
is associated with hyperinduction of chemokines and cyto-
kines, suggesting that intrinsic viral properties may contribute
to the increased levels and to pathogenesis [15]. However,
serum levels of IL-6, IL-8 and MIP-1b in our subjects correlated
positively with pharyngeal H7N9 load (Fig. 2), which indicates
that the observed hypercytokinaemia and hyperchemokina-
emia might possibly increase viral replication, as revealed in
H5N1 infection [15].
The laboratory ﬁndings for H7N9 patients were also similar
with H1N1 or H5N1 virus-infected individuals. Pronounced
lymphopenia (<1.5 9 109 lymphocytes/L) was observed in all
patients, and thrombocytopenia was also a common ﬁnding (13
cases in 18 patients). Relative lymphopenia has been found to
be an early and reliable laboratory marker of inﬂuenza A H1N1
infection [16]. Similarly, it also appeared to be the most
common haematological abnormality in H7N9 patients. Previ-
ous studies demonstrated a reduction in the number of CD4+
and CD8+ T cells in mice infected with a highly virulent
inﬂuenza A (H5N1) virus isolated from humans, and apoptosis
through Fas–Fas ligand signalling in lymphocytes after exposure
to inﬂuenza A virus [17,18]. This may help to explain the
transient lymphopenia in patients with inﬂuenza A virus
infection and could be a possible mechanism of disease
pathogenesis. Though no signiﬁcant survival difference was
found between patients with lymphocyte counts >0.5 9 109
cells/L and patients with lower counts (p 0.0838), a lympho-
cyte count <0.5 9 109 cells/L was identiﬁed as a risk factor for
adverse clinical outcome of H7N9 infection through univariate
logistic analysis. Lymphocyte counts might be regarded as an
important marker for evaluating infection severity and as an
early predictor of the clinical outcome.
As an acute-phase protein, CRP serves as a useful marker
for infection and inﬂammation. Signiﬁcantly high levels of
serum CRP were present in all patients in the current study,
indicating a severe inﬂammatory response to H7N9 virus.
Zimmerman et al. reported that serum CRP was an early
predictor of clinical outcome in patients with pandemic H1N1
inﬂuenza [19]. Similarly, serum CRP >90 mg/L was also
correlated with adverse clinical outcome through univariate
logistic analysis. A signiﬁcant survival difference was also
observed between patients with serum CRP <90 mg/L and
those with higher levels, suggesting that CRP may serve as a
useful biomarker for predicting disease severity among H7N9
patients.
In summary, knowledge of clinical features, potential com-
plications and risk factors discussed in the current study might
be helpful in evaluating disease severity and making proper
clinical decisions. Though no speciﬁc routine laboratory ﬁnding
for distinguishing H7N9 infection from previous pandemic
inﬂuenzas could be determined, clinical laboratory investigation
could be very helpful in following up management. Our data
demonstrated that high viral load, and the resulting intense
inﬂammatory responses, played an important role in H7N9
pathogenesis. Though immunomodulatory treatment has
potential beneﬁts at this stage, the focus of clinical management
should be on preventing the intense cytokine response by early
diagnosis and effective antiviral treatment.
There are several limitations in our study. First, the case
series probably represents patients with symptoms severe
enough to present for medical care, the full spectrum of H7N9
inﬂuenza in Shanghai was not fully described. Second, only 18
patients were included and could only be divided into two
groups according to the treatment outcome. This sample size
is too small for robust investigation of patterns in subgroups of
patients. Factors associated with clinical outcome could not be
veriﬁed through multivariate logistical analysis. Third, as some
patients had received antiviral therapy before admission, no
baseline viral load without treatment is available. It became
impossible for us to determine the viral dynamics in natural
history of H7N9 infection.
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